Table 2 Clinical features at baseline.
Baseline eye-level clinical features | ||||
|---|---|---|---|---|
DMO (N = 2107) | CRVO (N = 413) | BRVO (N = 757) | Overall (N = 3227) | |
Baseline VA (ETDRS letters) | ||||
Mean (SD) | 61 (16) | 47 (21) | 56 (17) | 58 (17) |
Median (IQR) | 65 (18) | 50 (27) | 59 (24) | 61 (20) |
Baseline VA greater than or equal to 70 ETDRS letters | ||||
<70 | 1367 (64.9%) | 357 (86.4%) | 569 (75.2%) | 2293 (70.0%) |
70 or over | 740 (35.1%) | 56 (13.6%) | 188 (24.8%) | 984 (30.0%) |
Baseline central subfoveal thickness (microns) | ||||
Mean (SD) | 420 (120) | 510 (170) | 440 (140) | 430 (140) |
Median (IQR) | 400 (140) | 510 (240) | 430 (200) | 410 (170) |
Intraretinal fluid (nL) | ||||
Mean (SD) | 76 (85) | 150 (150) | 130 (120) | 97 (110) |
Median (IQR) | 47 (86) | 110 (180) | 91 (140) | 62 (110) |
Subretinal fluid (nL) | ||||
Mean (SD) | 80 (350) | 380 (730) | 340 (660) | 180 (510) |
Median (IQR) | 0.12 (15) | 47 (430) | 25 (390) | 1.4 (67) |
Phakic status | ||||
Aphakic | 3 (0.1%) | 0 (0.0%) | 1 (0.1%) | 4 (0.1%) |
Phakic | 1170 (55.5%) | 315 (76.3%) | 562 (74.2%) | 2047 (62.5%) |
Pseudophakic | 564 (26.8%) | 86 (20.8%) | 174 (23.0%) | 824 (25.2%) |
Missing | 370 (17.6%) | 12 (2.9%) | 20 (2.6%) | 402 (12.3%) |
Anti-VEGF agent | ||||
Aflibercept | 1355 (64.3%) | 385 (93.2%) | 514 (67.9%) | 2254 (68.8%) |
Ranibizumab | 752 (35.7%) | 28 (6.8%) | 243 (32.1%) | 1023 (31.2%) |
